Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Department of Clinical Pharmacy, Utrecht University Medical Center, Utrecht, The Netherlands.
Bioanalysis. 2020 Oct;12(19):1405-1425. doi: 10.4155/bio-2020-0204. Epub 2020 Sep 25.
Therapeutic monoclonal antibodies (mAbs) are rapidly taking over the treatment of many malignancies, and an astonishing number of mAbs is in development. This causes a high demand for quantification of mAbs in biomatrices both for measuring therapeutic mAb concentrations and to support pharmacokinetics and pharmacodynamics studies. Conventionally, ligand-binding assays are used for these purposes, but LC-MS is gaining popularity. Although intact (top-down) and subunit (middle-down) mAb quantification is reported, signature peptide (bottom-up) quantification is currently most advantageous. This review provides an overview of the reported bottom-up mAb quantification methods in biomatrices as well as general recommendations regarding signature peptide and internal standard selection, reagent use and optimization of digestion in bottom-up quantification methods.
治疗性单克隆抗体(mAbs)正在迅速取代许多恶性肿瘤的治疗方法,并且有大量的 mAbs 正在开发中。这导致对生物基质中 mAbs 定量的需求很高,既需要测量治疗性 mAb 浓度,也需要支持药代动力学和药效学研究。传统上,这些目的是使用配体结合测定法,但 LC-MS 越来越受欢迎。尽管已经报道了完整(自上而下)和亚基(中间向下)mAb 定量,但目前最有利的是特征肽(自下而上)定量。本综述提供了生物基质中报道的自下而上 mAb 定量方法的概述,以及关于特征肽和内标选择、试剂使用以及自下而上定量方法中消化优化的一般建议。